Synopsis

Source of validity: Scientific
Rating (out of 5): 3

L12-myoviridae refers to a specific group of bacteriophages within the Myoviridae family, known for their ability to infect and lyse certain bacterial species. The use of myoviridae phages, including L12, in treating infections is supported by a growing body of scientific research, especially as concerns about antibiotic resistance intensify. Myoviridae phages have been shown in laboratory and some clinical settings to effectively target and kill pathogenic bacteria, including drug-resistant strains, by attaching to bacterial cell surfaces and injecting their genetic material, ultimately leading to bacterial lysis.

Phage therapy, the practice of using bacteriophages to treat bacterial infections, has historical roots dating back to the early 20th century, but its scientific validation has increased in recent years due to advances in microbiology and genomics. Recent studies, including in vitro experiments, animal models, and a limited number of compassionate use cases in humans, suggest that L12-myoviridae phages can reduce bacterial loads and improve outcomes in infections that are refractory to antibiotics. However, large-scale randomized clinical trials are still limited, and regulatory approval remains cautious.

The evidence rating of 3 reflects moderate scientific support: well-established laboratory mechanisms, promising preclinical results, and some human case reports, but insufficient robust clinical trial data. Overall, the scientific community views L12-myoviridae and related phages as promising candidates for adjunct or alternative therapies against multidrug-resistant bacterial infections.

More about L12-myoviridae
More about Infection

Other ingredients used for Infection

Other health conditions supported by L12-myoviridae

Products containing L12-myoviridae